Clinical Trials Underway through the Multi-Disciplinary Tuberous Sclerosis Program:

Clinical Drug Trial of Everolimus for Refractory Partial-Onset Seizures in Individuals with Tuberous Sclerosis Complex

Investigators at Boston Children's Hospital are looking at the drug Afinitor® (also known as everolimus) to see its effect on seizure frequency and severity in individuals with tuberous sclerosis complex and partial-onset epilepsy. Individuals diagnosed with TSC and uncontrolled seziures between the ages of 2 and 65 years are eligible to participate. This trial involves three phases: baseline, core and extension. Participants in the trial will come to Boston Children's Hospital approximately 11 times during the baseline and core phases. The study visits will include blood draws, laboratory tests and other evaluations such as physical and neurological exams, brain imaging and neuropsychological assessments. At the end of the core phase, patients will be offered inclusion into the extension phase. The expected duration of this trial is 3 years.

Additional information about this trial can be found at Clinicaltrials.gov

For more information about this study, please contact study coordinator Rachel Friedman at rachel.friedman@childrens.harvard.edu or 617-919-3499.